Effectiveness and safety of rivaroxaban compared with low-molecular-weight heparin in cancer-associated thromboembolism.

Costa, Olivia S; Kohn, Christine G; Kuderer, Nicole M; Lyman, Gary H; Bunz, Thomas J; Coleman, Craig I

Costa, Olivia S; Kohn, Christine G; Kuderer, Nicole M; Lyman, Gary H; Bunz, Thomas J; Coleman, Craig I.

Afiliação

Costa OS; Department of Pharmacy Practice, University of Connecticut School of Pharmacy, Storrs, CT.
Kohn CG; Evidence-Based Practice Center, Hartford Hospital, Hartford, CT.
Kuderer NM; Evidence-Based Practice Center, Hartford Hospital, Hartford, CT.
Lyman GH; Department of Pharmacy Practice, University of Connecticut School of Medicine, Farmington, CT.
Bunz TJ; Division of Hematology and Seattle Cancer Care Alliance, University of Washington, Seattle, WA.
Coleman CI; Hutchinson Institute for Cancer Outcomes Research, Fred Hutchinson Cancer Research Center, Seattle WA.

Blood Adv ; 4(17): 4045-4051, 2020 09 08.

Article em En | MEDLINE | ID: mdl-32853381

Assuntos

Neoplasias; Tromboembolia Venosa; Adulto; Idoso; Anticoagulantes/efeitos adversos; Heparina de Baixo Peso Molecular/uso terapêutico; Humanos; Medicare; Neoplasias/complicações; Neoplasias/tratamento farmacológico; Rivaroxabana/efeitos adversos; Estados Unidos; Tromboembolia Venosa/tratamento farmacológico

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Temas: ECOS / Aspectos_gerais Bases de dados: MEDLINE Assunto principal: Tromboembolia Venosa / Neoplasias Tipo de estudo: Guideline / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Humans País/Região como assunto: America do norte Idioma: En Revista: Blood Adv Ano de publicação: 2020 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google